|
www posted:someone explain this please, people give to cancer charities to help find a cure and then people like Martin Shkreli buy up the drugs and sell it @ a massive mark up??? is this a thing??? That's Shkreli's apparent defense for the Daraprim increase; he told The New York Times that Turing needs the dough to invest in developing improved treatments for toxoplasmosis. But doctors told the paper that there's no pressing need for a new med in that field. One big question is why an older drug like Daraprim has no generic competition. The NYT points out that the brand's distribution is tightly controlled, which could make it tough for generics makers to get the supplies they need in order to develop their own versions. But even without generics, Turing could find that its sales strategy backfires. Buyers might decide to stock cheaper rival drugs instead, despite the fact that Daraprim is currently the generally accepted leader in the field.
|
#
¿
Sep 23, 2015 01:14
|
|
|
|
| # ¿ Apr 29, 2024 04:27 |
|